Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03471611 · ClinicalTrials.gov registry record · Phase 1
Study of Intracoronary CD34+ Cell Administration in Patients With Early Coronary Atherosclerosis
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT03471611: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT03471611 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 21 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03471611, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
How safe and effective are CD34+ cell intracoronary injections for treating coronary endothelial dysfunction (CED)?
Interventions
- DRUG Autologous CD34+ Cells
- DRUG Granulocyte Colony-Stimulating Factor (G-CSF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2018-06-15 |
| Est. Completion | 2020-10-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03471611
The ClinicalTrials.gov registry entry for NCT03471611 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Autologous CD34+ Cells is the first listed.
NCT03471611 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03471611 about?
NCT03471611 is a clinical study titled "Study of Intracoronary CD34+ Cell Administration in Patients With Early Coronary Atherosclerosis". How safe and effective are CD34+ cell intracoronary injections for treating coronary endothelial dysfunction (CED)?
What is the current status of trial NCT03471611?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2018-06-15. Estimated completion is 2020-10-02.
What interventions are being tested in trial NCT03471611?
The interventions under investigation include: Autologous CD34+ Cells (DRUG), Granulocyte Colony-Stimulating Factor (G-CSF) (DRUG).
Who is sponsoring clinical trial NCT03471611?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.